Fate Therapeutics, Inc.FATENASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-5.80%
↓ 206% below average
Average (39q)
5.46%
Historical baseline
Range
High:46.53%
Low:-37.72%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -5.80% |
| Q2 2025 | -5.86% |
| Q1 2025 | -13.31% |
| Q4 2024 | -3.00% |
| Q3 2024 | 0.13% |
| Q2 2024 | 7.67% |
| Q1 2024 | 1.01% |
| Q4 2023 | -7.17% |
| Q3 2023 | -16.15% |
| Q2 2023 | -37.72% |
| Q1 2023 | -24.73% |
| Q4 2022 | 9.24% |
| Q3 2022 | -1.83% |
| Q2 2022 | 12.71% |
| Q1 2022 | 3.77% |
| Q4 2021 | 30.84% |
| Q3 2021 | 10.63% |
| Q2 2021 | 7.07% |
| Q1 2021 | 15.06% |
| Q4 2020 | 27.00% |
| Q3 2020 | 15.09% |
| Q2 2020 | -8.91% |
| Q1 2020 | 16.14% |
| Q4 2019 | 8.65% |
| Q3 2019 | 7.26% |
| Q2 2019 | 22.02% |
| Q1 2019 | 25.78% |
| Q4 2018 | 3.36% |
| Q3 2018 | -18.90% |
| Q2 2018 | 46.53% |
| Q1 2018 | 16.07% |
| Q4 2017 | 15.26% |
| Q3 2017 | 8.21% |
| Q2 2017 | -0.49% |
| Q1 2017 | 27.87% |
| Q4 2016 | -8.44% |
| Q3 2016 | 0.32% |
| Q2 2016 | 2.20% |
| Q1 2016 | 22.14% |
| Q4 2015 | 8.59% |